ABLE 2013 Survey

Survey

INDUSTRY INSIGHTS

volume I

20 BioSpectrum | June 2013 | www.biospectrumIndia.com | A CyberMedia Publication

After recording growth rates close to the 18 percent during the last five years, the industry slipped further to register 15.08 percent growth. This is the lowest growth that the industry recorded in the past 11 years. The overall bioscience industry, comprising of the biopharmaceuticals, diagnostics, clinical and contract research services, enzymes, bioagri, and bioinformatics, recorded ` 23,524 crore in sales in 2012-13. The BioPharma, clinical trials and contract re-search sectors account for 82 percent market share today. The BioAgri sector, which has been growing over 20 percent during the last few years, has come crashing with only 5.2 percent growth. The reasons are obvi-ous. There has been complete lull in promotion of transgenic research and regulatory support.

The industry is clearly at an inflection point. Though it missed the $5 billion target, it has not lost hope. It is striving for $100 billion revenues in 2025. Association of Biotechnology Led Enterprises (ABLE) has been making efforts to move towards achieving the number. Dr P M Murali, managing director and CEO, Evolva Biotech and president, ABLE, is op-timistic that $100 billion is achievable if the gaps are filled in fast. Ad-hoc policies are not helpful and require more stringent lawmaking say industry stalwarts. A comprehensive regulatory structure in the form of Biotechnology Regulatory Authority of India (BRAI) needs urgent ap-proval by the Parliament to restore the confidence of the industry and kickstart growth.

Industry at Inflection Point

Industry Insights

BIOSPECTRUM ABLE SURVEY


0

10000

20000

30000

40000

50000

2012-132011-122010-112009-102008-092007-082006-072005-062004-052003-042002-03

2345

3475

4745

6521

8541

10272

12137

14199

17249

20440

23524

BioPharma

BioServices

BioAgri

BioIndustrial

BioInformation

Total Industry

Biotech industry records `23,524 crore in FY 2012-13

Biotech industry in 2012-13BioPharma

BioServices

BioAgri

BioIndustrial

BioInformatics

Total Industry

`14,923 crore

`4,329 crore

`3,210 crore

`772 crore

`290 crore

`23,524 crore

17.69%

15.47%

5.23%

10.91%

9.14%

15.08%

Industry Insights



Biotech industry registers 15.08% growth

BioPharma industry still accounts for over 60% marketshare.

BioServices records 15.5% growth

BioAgri registers 5% growth.Biotech exports cross `12,000 crore, register

22% growth.

Industry Insights

0

5000

10000

15000

20000

25000

2011-122010-112009-102008-092007-082006-072005-062004-052003-042002-03

4,7

45 6,5

21 8

,54

1 10

,272 12

,137

14

,199

17

,249

20

,441

23,5

24

2001 3

357 4

937

5732

7152

7531

8852 9

842

2744 31

64 3604 4

540

4985

6668

8397

1059

.9

2013-14

1201

2

1151

2

Total Biotech

Domestic

Exports

1019

1326

1516

1959

3,4

75

2,3

45



The BioServices sector

registered 18%

The industry growth rate is now

around the 18% The industry grew at a CAGR of 14.15% during the last five years

The BioPharma sector is currently growing

at a CAGR of 13.61%. over the past five years

BioServices growth rate 2003-13

Biotech industry growth rate 2003-13

Industry Insights

0

10

20

30

40

50

2011-122010-112009-102008-092007-082006-072005-062004-052003-04

48.0

0

37.0

0

37.0

0

31.0

0

20.0

0

18.0

0

17.0

0

21.0

0

19.0

0

2011-12

15.0

0

0

20

40

60

80

100

120

2011-122010-112009-102008-092007-082006-072005-062004-052003-04

104.

00

55.0

0

69.0

0

53.0

0

43.0

0

31.0

0

28.0

0

23.0

0

16.0

0

2012-1315

.50

0

10

20

30

40

50

60

2011-122010-112009-102008-092007-082006-072005-062004-052003-04

54.0

0

30.0

0

32.0

0

27.0

0

16.0

0

14.0

0

12.0

0

21.0

0

19.0

0

2012-13

18.0

0

BioPharma growth rate 2003-13



BioIndustrial Sector grew by 11% to record `772 crore

BioIndustrial sector recorded 9% growth

Industry Insights

0

50

100

150

200

2011-12 2012-132010-112009-102008-092007-082006-072005-062004-052003-04

18.0

0

154.

00

81.0

0

55.0

0

30.0

0

18.0

0

37.0

0

28.0

0

23.0

0

5.23

0

5

10

15

20

25

30

35

2011-122010-112009-102008-092007-082006-072005-062004-052003-04

1.00

34.0

0

17.0

0

5.00

4.00

17.0

0

18.0

0

11.0

0

11.0

0

2012-13

11.0

0

0

5

10

15

20

25

30

35

2011-122010-112009-102008-092007-082006-072005-062004-052003-04

7.00

25.0

0

20.0

0

21.0

0

31.0

0

16.0

0

5.00 5.00

10.0

0

2012-13

9.00

BioAgri is slowing and only a clear

policy to infuse GM technology can change the fortunes of Indias agribiotech industry

BioAgri growth rate 2003-13

BioIndustrial growth rate 2003-13

BioInformatics growth rate 2003-13

BIOSPECTRUM ABLE SURVEY BIOSPECTRUM ABLE SURVEY

A CyberMedia Publication | www.biospectrumIndia.com | June 2013 | BioSpectrum 29

Segment share of biotech export (% share)

Industry Insights

0

20

40

60

80

100

120

2012-132011-122010-112009-102008-092007-082006-072005-062004-052003-042002-03

bioInformatics bioIndustrial bioagri bioservices biopharma

68

12

1

13

7

76

14

1

54

74

20

113

70

26

113

74

21

112

68

2711

2

63

33

12

1

63

34

12

1

63

33

22

1

65

32

12

1

73

20

134

Exports account for 52% share of the BioPharma sector.Total domestic sales for the year stood at `11,512 crore



Industry Insights

Export

Export

DO

MES

TIC

DO

MES

TIC

DO

MES

TIC

Export

Export

Export

DO

MES

TIC

DO

MES

TIC

DO

MES

TIC

Export

Export

Export

DO

MES

TIC

DO

MES

TIC

DO

MES

TIC

Export

Export

Export

Export

Export

Export

DO

MES

TIC

DO

MES

TIC

DO

MES

TIC

0

1000

2000

3000

4000

5000

6000

7000

p Op O p O p O

2003-0 2003-0 2005-06 2006-07

250

2088 69 25

160

162

11

1464

391

23 51 72

2106

3430

726

928

2495

684

36 4110

1

2213

3656

233

419

3673

1052

47 4512

0

2300

5087

935

025

2007-08

399 9

1502

52 3015

0

2900

7011

5038

040

42

Total BT Revenue4745

Export Domestic 2001 2744



Export Domestic 4937 3604


Export Domestic5732 4540

2003-13

BioInformatics

BioIndustrial

BioAgri

BioServices

BioPharma

* All revenues in `crore

Industryindian Biotech


004-05


Export

Export

DO

MES

TIC

DO

MES

TIC

DO

MES

TIC

Export

Industry Insights

Export

Export

DO

MES

TICE

xport

Export

Export

DO

MES

TIC

DO

MES

TIC

DO

MES

TIC

Export

Export

Export

Export

Export

Export

Export

DO

MES

TIC

DO

MES

TIC

DO

MES

TIC

Export

Export

Export

DO

MES

TIC

DO

MES

TIC

DO

MES

TIC

DO

MES

TIC

DO

MES

TIC

DO

MES

TIC

2008-09 2009-10 2010-11 2011-12

4868

1964

61 89

170

3015

9814

3338

950

4768

2507

5812

474

4061

132

1878

440

157

5535

2986

7415

010

6

5110

260

2406

476

146

6213

3224

153

167

85

6467

525

2898

529

181


Export Domestic7152 4985




Survey & ranking methodology BioSpectrum conducted this survey jointly with the Association of Biotechnology Led Enterprises (ABLE). BioSpectrum and ABLE have jointly been doing this exercise since 2003. A detailed questionnaire (survey form) was sent to over 200 com-panies to capture the needed information for the analysis. This was done during April-May 2013. Companies shared informa-tion with us to the extent it was possible by them.

The revenues considered for the analysis are biotech products sales and service figures. In several cases, where revenue figures were not available, estimates were arrived in discussion with industry experts. These are denoted (*) as BioSpectrum Estimates.

This year in the list of Top 20 companies, biotech focused companies across the life sciences spectrum have been consid-ered, including diagnostics space.

Biotech suppliers revenues are not considered/included in this analysis. BioPharma segment included products made by fermentation/animal cell culture (not animal extracts) and plant cell cul-ture (not plant extracts).

The BioAgri segment analysis includes only the GM seeds and molecular markers and related products. So, the hybrid seeds business is not a part of the agri-business sales values.

The BioServices segment analysis includes the contract as well as clinical research services revenue. For all the ranking purposes, we have taken the biotech business only into consideration. Wherever TURNOVER is men-tioned, it means, sales turnover from biotech. Therefore, turnover wherever mentioned is not necessarily the total sales turnover of the company.

Industry Insights




Serum Retains No. 1 Position

BioSpectrum ABLE Top 20 Biotech Companies

Serum Institute of India becomes the first biotech company in India to cross the `2,000 crore mark. Biocon is the second largest biotech company, followed by Nuziveedu Seeds.

Our 11th annual list of bioscience companies by revenues.

Rank 2013

Company BioScience Revenues in Rs Crore %Change over 2011-122012-13 2011-12 2010-11

1 Serum Institute of India 2374.00 1708.00 1041.00 38.99

2 Biocon 1871.00 1676.40 1483.00 11.61

3 Nuziveedu Seeds 778.13 745.00 610.00 4.45

4 NovoNordisk* 712.00 647.28 462.00 10.00

5 Syngene International 557.00 410.00 318.00 35.85

6 Reliance Life Sciences* 535.00 401.00 283.00 33.42

7 Eli Lilly* 391.66 290.16 204.00 34.98

8 Bharat Serums and Vaccines 389.00 298.32 226.00 30.40

9 Biological E 353.00 98.96 246.39 256.71

10 Fortis Clinical Research Ltd (FCRL) 344.40 287.00 86.00 20.00

11 Novozymes South Asia* 343.00 297.66 242.00 15.23

12 Ankur Seeds 341.00 325.00 250.00 4.92

13 Indian Immunologicals 325.65 255.93 269.07 27.24

14 GlaxoSimthKline* 312.00 257.66 177.51 21.09

15 Bharat Biotech 299.83 277.70 265.00 7.97

16 Tulip Group 260.00 225.00 185.63 15.56

17 Haffkine Bio-Pharmaceutical 253.41 160.02 86.00 58.36

18 Mahyco 246.00 314.00 359.00 -21.66

19 Advanced Enzymes 229.36 180.00 154.00 27.42

20 Rasi Seeds 229.00 392.00 371.88 -41.58

Profiles

Ranking


BioSpectrum ABLE Top 20 Biotech Companies

Top 3 companies account for 24.38 percent market share.

Top 20 companies account for 47.37 percent share of the total biotech industry of `23,452 crore

Rank 2013

Company BioScience Revenues in Rs Crore %Change over 2011-12w2012-13 2011-12 2010-11

22 Krishidhan Seeds 199.81 173.80 276.13 14.97

23 Panacea Biotec* 190.00 384.00 928.41 -50.52

24 Concord Biotech 174.50 145.01 126.17 20.34

25 Bharat Immunologicals & Biologicals Corporation 172.78 48.55 0.00 255.88

26 Ecron Acunova 153.00 146.00 117.00 4.79

27 Anthem Biosciences 140.00 100.20 78.00 39.72

28 Dr Reddy's Laboratories 110.00 88.00 66.00 25.00

29 Span Diagnostics 99.47 58.52 0.00 69.98

30 Advinus Therapeutics* 97.00 53.00 90.00 83.02

31 RFCL (Diagnova) 73.20 65.00 56.00 12.62

32 Max Neeman International 70.00 54.66 46.17 28.06

33 Hester Biosciences 61.90 48.26 41.97 28.26

34 Ocimum Biosolutions* 60.00 49.00 65.00 22.45

35 Cadila Healthcare* 57.34 56.50 52.31 1.49

36 Strand Life Sciences* 55.00 49.14 42.00 11.93

37 Maps Enzymes 54.28 58.00 48.00 -6.41

38 Oncquest Laboratories 48.00 40.00 16.00 20.00

39 Camson Biotechnologies 24.45 16.43 -- 48.81

40 Celestial Biolabs 21.60 20.58 25.22 4.96

41 Auriga Research 21.00 15.00 8.00 40.00

42 Bhat Biotech* 15.00 14.00 12.11 7.14

43 Transgene BioTek 15.00 26.25 7.00 -42.86

44 Sphaera Pharma 12.50 -- -- --

45 Sandor Proteomics 11.05 4.50 -- 145.56

46 Fermenta Biotech 10.50 -- -- --

47 Aumgene Biosciences 8.60 6.80 -- 26.47

48 Vivan Life Sciences 8.02 7.34 4.15 9.26

49 Dabur research Foundation 8.00 5.37 0.00 48.98

50 Imgenex 6.00 4.00 3.00 50.00

51 Growmore Biotech 3.60 2.60 -- 38.46

52 Navya Biologicals 3.30 2.15 2.50 53.49

53 Caprienzymes 3.00 -- -- --

54 Xcyton* 2.00 1.50 1.50 33.33

55 NovoInformatics 0.80 0.20 0.00 300.00

56 3B Blackbio Biotech India 0.68 0.46 -- 47.83

Profiles

Ranking


are in the late stages of development as well. The first to come out in the market will probably be the Vero cell rabies vaccine followed by the Rota-virus and Pneumococcal vaccines.

SII bagged major orders for its pen-

tavalent vaccines, Pentavac, which was administered in Kerala and Tamil Nadu. SIIs brand of measles (M-Vac), MMR (Tresivac), TT and quadravalent (SII Q Vac) vaccines too were supplied in large quantities. SII also joined the oral polio vaccine list of manufacturers in 2013. This decision was made after UN agencies anticipated a shortage in OPV doses.

A lot of Serums success sto-ry stems from the vision of Dr Poonawalla who foresaw the need to build manufacturing sites with larger capacities in anticipation of higher demand. Senior officials state that SII today has broadened its mar-ket reach as its current capaci-ties exceed the requirements of UN agencies.

SII also has set an ambitious goal of launching one vaccine per year, for the next few years. A major project at SII has been the Rotavirus vaccine, which is currently in Phase III trials. A stand alone Pneumococcal vaccine and a Vero cell rabies vaccine

One new vaccine per year goal

While staying focused on vaccines, SII also ventured into the biophar-maceutical arena, with the launch of its own brand of erythropoetin (EPO). A separate dedicated facil-ity for bipharmaceuticals is current-ly being used for the same and it is being expanded to allow large scale manufacturing of other products as well. SII is also researching the pro-duction of monoclonal antibodies, which it hopes to launch in the next two years.

In July 2012, SII made its first overseas acquisition with Dutch biologics company Bilthoven Biologicals. This acquisition will significantly strengthen our position in the global vaccines market, while giving us access to the tech-nology and production facil-ity of Injectable Polio Vaccine

(Salk), which is the only logical so-lution available to the world for the eradication of polio, said Dr Poon-awalla. Currently at SII, the global eradication of polio is an important prerogative. With the impending adoption of the next phase of the Global program for Polio eradica-tion, this could prove to be a game changer. BS

With a whopping 39 percent growth, Serum Institute of India (SII) has retained its numero uno position in the Indian biotech industry recording revenues of `2,374 crore for 2012-13.

CoMpanYSerum Institute of India

BuSineSSvaccines and biopharmaceuticals

Revenue2013 `2,374 crore

Bilthoven Biologicals acquisition gives the Poonawalla Group

an important operational and strategic beachhead in Europe and the US. This will also significantly enhance its earlier offerings in the

pediatric vaccines.

Chairman and Managing Director: Dr Cyrus Poonawalla

biotech companies

TOP 20


ent expiry of eight of the top 10 bio-tech products by 2018 will boost the Indian generics market. From about five percent of Biocons sales in FY 2012, the contribution of this seg-ment is expected to grow to over 10 percent by 2015, when the company is projected to achieve total sales of $700 million. Biocons biosimilar

business also offers a promising port-folio of recombinant human insulin and insulin analogs. It is developing more complex biosimilar biologics, including monoclonal antibodies (mAbs), for the global market.

Moving forward, the company hopes to ink licensing and marketing deals especially in the rest-of-the-world markets for its insulin products. It sells recombinant human insulin (Insugen) in India and also has ap-

Registering 13 percent growth over the last fiscal year, Biocon ended FY 2012-13 with total biopharmaceu-tical revenues of `1,871 crore. The key contributors to Biocons growth have been research services, branded formulations and growing biosimilar business, led by generic insulin. The companys insulin franchise contin-ues to garner market share across India and emerging markets and now accounts for more than 10 percent of its sales.

Biocon is equally upbeat about its biosimilars. The company expects the sales revenue from this segment to treble by FY 2015. It hopes the pat-

Global Top 20 biotech employer

provals to sell it in more than 40 countries. The biosimilar insulin glargine (Basalog) is available in the Indian market and it has approvals to sell it in over five countries. The global phase III trial for biosimilar Trastuzumab for treating cancer has gained further traction with ongoing recruitment and trial approval in ma-jor European countries. It has also completed patient recruitment in a separate Phase III trial for the drug in India.

In another significant develop-ment of the last fiscal year, Biocon enhanced its partnership with Mylan Inc. through the re-licens-ing of three biosimilar insulin an-alog products for the global devel-

opment and commercialization. The partnership with Mylan endorses the intrinsic value of this asset and sig-nificantly reduces its burden of devel-opment costs involved in global com-mercialization. Looking ahead, the company intends to sustain growth momentum by optimizing its small molecules portfolio, further expand-ing its insulin footprint in emerging markets, and continuing to deliver robust growth in branded formula-tions and research services. BS

Having forged strategic partnerships with the Mylan and BMS to consolidate its key insulin business, Biocon emerged even stronger in 2012.

CoMpanYBiocon

BuSineSSBiopharmaceuticals and branded formulations

Revenue2013 `1,871 crore

Science magazine features Biocon in its annual list of

Global Top Twenty Employer

Chairman And Managing Director: Dr Kiran Mazumdar-Shaw,

biotech companies

TOP 20


hybrids like Uttam, Raghav, and Shalimar. Despite the fact that the area is set to reduce even further by 8-9 percent, NSL has plans in place to increase its cotton market share from 25 percent to 30 percent by in-troducing new varieties, creating and

promoting a brand identity and having an exclusive marketing team dedicated to cotton only. Of all the hybrids approved by the GEAC, NSL has contributed to almost 16 percent. Today, it has 179 hybrids approved by GEAC till 2012 as against 1,128 total hy-brids approved in India

Currently almost half (40-45 per-cent) of the total cotton produc-tion in the country can be traced to the cotton hybrids developed by Nuz-iveedu Seeds (NSL). This year, NSL launched two new Bt cotton products Sona and Surakhsha, both of which are suitable for varied agro-climatic zones of India.

The Bt cotton market is en-countering a stagnation in the amount of area under cultiva-tion. The total area decreased by 6 percent in 2012-13 as compared to the previous year. Regardless, this year, NSL strategically improved the sales of new promising

Undisputed leader in Bt cotton

biotech companies

NSL has been an early starter in en-tering into collaborations with state governments through PPPs. The Ma-harashtra government sanctioned a PPP project with NSL in 2012 to improve cotton productivity by 30 percent in the drought prone Vidarb-ha region, while covering around 10,000 acres. This project was found to be very successful with an average increase in yield by 50 percent, and in some cases up to a 100 percent in-crease. Due to this achievement, the

same project is planned for this year as well, to cover a to-tal of 20,000 acres.

In order to increase the per acre yield of crops, Nuziveedu Seeds has been taking up ex-tension services to the farmers in big way. The state govern-ments of Uttar Pradesh and Maharashtra have invited the company for a Public-Private

partnership for its extension work which benefits more than two mil-lion farmers annually. In lieu of such activities, The Cotton Research and Development Association awarded Nuziveedu Seeds the Public Private Partnership-2012 award for its work in the seed industry. BS

Nuziveedu Seeds has maintained its leadership position in the Bt cotton market by generating revenues of `778.13 crore in FY 2012-13.

CoMpanYNuziveedu Seeds

BuSineSSProduction and marketing of seeds

Revenue2013 `778.13 crore

NSLs marketing network comprises of 8 regional offices, six C&F agents, 2,500 distributors, and over 59,000 dealers spread across 17 states of the country. At last count, NSLs seeds are used by more than 5.5 million

farmers of the country.

Chairman and Managing Director: M Prabhakar Rao

TOP 20


biotech companies

TOP 20

is that it is said to have a lower av-erage price as compared to its com-petitors. The price is also found to be lowest in India as compared to the other countries it operates in. Across the world too, Novo Nordisk is a leader in this therapeutic segment. In Europe Novo Nordisk is said to have more than 51 percent share in insulin space by volume. Novo Nor-disk in March announced Tresiba, a simple once-a-day injection, which

last for 40 hours instead of a maxi-mum of 18 hours.

Novo Nordisk has been focusing on its customer centric initiatives through various programs over the last few years. Changing Diabetes for Chil-dren is one such ongoing initiative partnered with the World Diabetes

Novo Nordisk has retained its leadership position in the dia-betes care segment in FY2012-2013 with estimated revenues of `712 crore. The company recorded over 10 percent growth in this segment. The product portfolio is a healthy mix of different types of insulins. It con-sists of NovoRapid (a rapid-acting analogue), NovoMix (a premix ana-logue), Levemir (long-acting basal insulin), Victoza, Human insulins like Actrapid, MixTard and Insulatard. Addi-tionally Novo Nordisk also markets its insulin delivery device, Novo-Pen that is available for use with appropriate types of insulin.

One of the features in favour of Novo Nordisk

Emphasis on patient awareness

Foundation and local governmental bodies, in various countries including India that looks at children with Type 1 diabetes and tries to improve access to necessary medication.

Novo Nordisk has also been creating awareness about diabetes among the general population as well. It had or-ganized a unique diabetes exhibition aimed at creating awareness about dia-betes among the people in Bihar along with providing free diabetes screening for the participants. Such efforts have been replicated elsewhere as well.

Novo Nordisk has a long standing agreement with Torrent Pharma for the formulation and packaging of Insulin, exclusively for Novo Nordisk to be carried out by the latter. Tor-rent has been manufac-turing insulin for Novo Nordisks India require-

ment for more than 15 years now.

In addition to its activities in the insu-lin space, Novo Nordisk also markets its brand of growth hormone, Nor-ditropin. It also produces a recombi-nant Factor VIIa marketed under the name NovoSeven for the treatment of haemophilia A and B. BS

While maintaining its position in the Indian insulin market, Novo Nordisk has stepped up its patient awareness programs to build customer trust.

CoMpanYNovo Nordisk

BuSineSSInsulin and insulin anal

Revenue2013 `712 crore*

Novo Nordisk has a long standing agreement with Torrent Pharma for the formulation and

packaging of Insulin, exclusively for Novo Nordisk to be carried out by the latter.

Torrent has been manufacturing insulin for Novo Nordisks India requirement for more

than 15 years now.

Managing Director: Melvin Oscar Dsouza


pany recorded robust turnover of `557 crore in revenue as compared to `410 crore in FY 2011-12.

During the last fiscal, the company signed an agreement with GE Equity International Mauritius, a subsidiary

of GE Capital Corporation, which will make a primary equity investment in it. As per the terms of the agreement, GE Capital would invest `125 crore for a 7.69 percent equity share in Syngene. The company believes that it is an endorsement to the quality of innovation and the role played by its scientific team in accelerating inno-

Established in 1994 as a subsidiary of Biocon, Syngene is an interna-tionally recognized custom research and manufacturing organization, which supports R&D programs from lead generation to clinical supplies. Among Indias leading contract re-search organizations, Syngene offers integrated drug discov-ery and development services with capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process re-search and development, and formulation development for small and large molecules. During FY 2012-13, the com-

Milestone year

biotech companies

vation and productivity of its global customers. Also, the deal has estab-lished the standard valuation of the company which it felt was low earlier and hindered its plans for listing in capital markets. However, the com-pany has ruled out the listing of the company any sooner.

In another development, Syngene in a strategic partnership with Abbott, one of Indias largest healthcare compa-nies, launched the first of its kind, The Abbott Nutrition Research and Development Center. The state-of-the-art center will focus on the de-velopment of science-based, affordable nutrition products for the country and enable the expansion of Abbotts nutri-

tion product portfolio at Biocon Park in Bangalore. The combined market insights and nutrition science exper-tise of two organizations will enable them to address the healthcare and nutritional challenges of an emerging economy like India across a diverse range of diseases that straddle both infectious and chronic maladies. BS

Syngenes revenues cross $100 million threshold for the first time. In FY 2012-13, the companys deal with GE Capital has unlocked the true valuation of the company.

CoMpanYSyngene International

BuSineSSDrug discovery and development services

Revenue2013 `557 crore

Syngene has an expert team of over 1,500 scientists and 1 million

sq. ft. of built-up laboratories equipped with state-of-the-

art infrastructure to support the research and development

programs of global pharma, biotech and nutrition companies.

Director: Peter Bains

TOP 20


Life Sciences, says, For biosimilars, we are looking to form partnerships

or licensing deals with other compa-

n i e s to target specific markets and allow for mutual growth. Dur-ing this year, we signed several out-licensing deals for biosimilars and pharmaceutical products with com-panies across the globe. We can be

a global player in biosimilars in the years to come. The company also re-

ceived 12 overseas prod-uct registrations during the year.

The biopharmaceuti-cals portfolio consists of plasma proteins, which have grown significantly, biosimilars, and recom-binant proteins. RLS has the only manufacturing

Of the different segments that Reliance Life Sciences (RLS) operates in, including regenera-tive medicine, molecular medicine, cord blood banking, APIs and more, biopharmaceuti-cals showed the maximum growth. RLS has followed a strategy of de-veloping products first for the Indian market, followed by ROW markets and, eventually, to developed markets. Mr KV Subrama-niam, president and CEO, Reliance

On a scale up mode

facility in South Asia that produces a broad portfolio of plasma proteins. Eight new products were launched during FY 2012-13.

An in-house CRO currently handles an equal amount of internal projects as well as those commissioned from other institutes. Other emerging departments include regenerative medicine and molecular medicine, which are set to play a bigger role in

the future.

RLS has a strong pipeline of prod-ucts in the cat-egories of oncol-ogy formulations, stem cell thera-pies and tissue engineered prod-

ucts as well. Other emerging areas of research at RLS include novel pro-teins, especially fusion proteins and novel monoclonal antibodies, siRNA molecules for treatment of dengue and cancer, some of which are their long term projects. Research is also being conducted in other poorly re-searched disorders such as brain stroke, incontinence, and more. Dur-ing the past year, 10 biopharmaceuti-cal products entered advanced clini-cal development phase. BS

A part of one the largest conglomerates in India, Reliance Life Sciences, has for over a decade quietly and steadily built one of the largest pipeline in biosimilars in the world. Over the last year, its revenues grew by 33 percent to `535 crore.

CoMpanYreliance life Sciences

BuSineSSBiopharmaceuticals, pharmaceuticals, clinical research services, regenerative medicine and molecular medicine services

Revenue2013 `535 crore (estimates)

RLS has the largest number of biosimilar products in the Indian market including erythropoietin, tissue Plasminogen

Activator, FSH, HCG, IFN beta, IFN gamma and more. Products in the pipeline include those for cardiac care, oncology, rheumatoid arthritis. Some of these include

monoclonal antibodies as first line therapies which are now in clinical trials and should hit the market soon.

President and CEO: KV Subramaniam

biotech companies

TOP 20


working closely with the government, healthcare providers and local com-munities to expand treatment access and improve outcomes for patients.

With the goal of improving patient quality of life and increasing posi-tive self-care behavior and control of

diabetes, Lilly India has introduced Diabetes Educator Service. This com-prehensive and sustainable approach provides education and counseling on diabetes, nutrition, lifestyle man-agement and appropriate way to use Lilly injectable devices prescribed by treating physician.

In September 2011, Eli Lilly had an-nounced the launch of a new open innovation platform designed to help build the companys pipeline of to-morrow and, from a philanthropic perspective, identify molecules that

With an annual growth of close to 35 percent, Lillys seven products from biotech stable include human insulin (Huminsulin), human insulin analogues (Humalog), hu-man growth hormone (Humatrope), teriparatide (Forteo), Drotrecogin Alfa (Xigris), ReoPro (Abciximab-monoclonal antibody) and Exenatide (Byetta). The anti-diabetes product range roughly contributes for 60-65 percent of the Lilly Indias revenue.

After the change in guard at its Indian operations in late 2011, Lilly not only restructured its sales and marketing structure but also is now

Expanding horizons

biotech companies

may have application for treating multi-drug resistant tuberculosis (MDR-TB). The company also en-tered into collaboration with the Strides Arcolab to expand delivery of cancer medicines in the emerging markets. As a part of this arrange-ment, the company will in-license

a portfolio of high-quality, branded generic injectible and oral cancer medicines from Agila Specialties, the special-ties division of Strides Arco-lab, based in Bangalore, India.

The company also continues to work on the global Lilly MDR-TB Part-nership which was first announced in 2003 to confront multi-drug resis-tant tuberculosis, a disease so daunt-ing that no single organization can fight it alone. Since then, this unique public-private partnership with total plan outlay of nearly $135 million has mobilized 25 partners across the five continents to tackle the scourge of TB and MDR-TB. The Partner-ship in India works in close coordi-nation with the National TB Control Program. BS

Counted among the few top insulin market players of India, Lilly and Company has successfully witnessed consistent growth since commencement of its operations in1993. In the FY 2012-13, Eli Lilly India is estimated to have garnered `391.66 crore in revenues.

Chairman and Managing Director: Melt van der Spuy

TOP 20

CoMpanYeli lilly India

BuSineSSBiopharmaceuticals for diabetes, cancer, sepsis, osteoporosis, cardiovascular disorders and growth hormone deficiency


Lilly India continues to spearhead the Uday, an intensive five-year program

aiming to fight the rising burden of non-communicable diseases in India.


researches natural products for their platforms in biotech, biologicals and new drug delivery along with animal health.

Dr Gautam Daftary, vice chairman and managing director, Bharat Se-

rums and Vaccines says, In 2013-14 period, our main goal is to finish the regulatory filings for the products I have mentioned earlier. Hopefully, we will see our products commer-cialize. We have to maintain a bal-ance with the R&D so that we reap dividends as well.

A few months ago, BSV announced its plans to enter into the area of rapid diagnostic testsfor malaria

Started as a blood products compa-ny, Bharat Serums and Vaccines now has operations in everything ranging from biosimilars and stem cells to diagnostics.

Bharat Serums and Vaccines (BSV) with revenues touching `389 crore in FY2012-13 recorded 30 percent growth over the previous fiscal. BSV today has 2,500 people spread across various divisions both in India and abroad. BSV Biosciences in USA focuses on biotechnologi-cal research, while another re-search unit in Germany specifically

Diversifying services

and later HIV. A separate venture for molecular biology based diagnostics for detecting inborn errors of me-tabolism in newborns is also in the works. These would be its entry prod-ucts into the diagnostic range. Addi-tionally, it also set up a joint venture with Morpheus, a German company under which BSV set up around 30 IVF clinics in India with plans of fur-ther expansion.

An important product from In-dias point of view to come out of BSVs stables is for the treatment

of kala azar. BSV has a glob-al patent for Amphotericin emulsion(Ambisome).

BSV recently launched in In-dia Ulinastatin, a biosimilar for the treatment of sepsis. Sepsis today, is the leading cause of fatalities, with more

65% mortality associated with it. Lack of treatment options prompted BSV to carry out research in natu-ral products at the Dusseldorf to develop the product isolated from urine, a serine protease that sup-presses polymorphonulear elastase (PMNE). There is only one product like this which has a market size of $250 million. BSV hopes to utilize UK as an entry point for Europe by 2013-2014. BS

More than four decades after its first product was launched, Bharat Serums and Vaccines is now all set to introduce niche products that address unmet needs.

CoMpanYBharat Serums and vaccines

BuSineSSr&D, manufacturing and marketing of biopharmaceuticals


We have substantial pipelines at different stages of development and are looking at a $4-5 billion opportunity. We hope to capture

at least 10 percent of it.

Managing Director: Bharat Daftary

biotech companies

TOP 20


FY 2012-13, BE recorded total bio-tech revenues of Rs 353 crore as com-pared to the FY 2011-12 period when it had grossed Rs 98 crore. It is phe-nomenal growth rate of more than

250 percent over the last fiscal year. The companys product development efforts are driven by an internation-ally experienced management team through strategic partnerships with leading biotechnology and pharma-ceutical companies and research in-stitutes around the world.

In another major development, GAVI Alliance in April 2013 signed a sup-

Established in 1953 and based out of Hyderabad, Biological E (BE) has built a strong and balanced prod-uct pipeline that includes a range of vaccines marketed primarily within emerging markets. The company supplies several essential and lifesaving drugs to UNICEF, central and state government hos-pitals, public sector under-takings, the Indian armed forces and the domestic re-tail market.

Over a period of time, the company has consolidated its finan-cial performance remarkably. During

Phenomenal growth

ply agreement with BE, according to which it will receive the latters five-in-one vaccine for just $1.19 per dose, as compared to the 2012 weighted av-erage price of $2.17. UNICEF, an alli-

ance partner, managed the tender process for GAVI, which saw agreements made with Biological E and four other companies.

In September 2012, BE launched the countys first indigenous vaccine, JEEV, to prevent Japanese En-cephalitis. Priced at `985,

the vaccine filled a huge unmet medi-cal need. At the moment, there is no strong anti-viral therapy for this (Japanese Encephalitis) except for a vaccine that the government imports from China and its supply is limited. The vaccine will be made in Hyder-abad and that the technology has been obtained from Austrian vaccine maker Intercell. BS

Thanks to its best strategic decisions on product development and effective partnerships, Biological E registered 200 percent growth in its biotech business

CoMpanYBiological e

BuSineSSvaccines and Pharmaceuticals


Biological E has invested about `400 crore in the last four years to set up a vaccine production facility on the outskirts of Hyderabad. The facility will produce vaccines for tetanus, diphtheria, hepatitis B, as well as

JEEV and the pentavalent vaccines.

Managing Director: Mahima Datla

biotech companies

TOP 20


Within a short duration of eight years, FCRL has been able to garner major projects. During FY 2012-13, the company recorded revenues of `344.40 crore as compared to `287 crore in the FY 2011-12. It was one of the four CROs joining the Maximax

Pharmaceutical Research, which launched a global CRO alliance (CRO Development Group). The infra-structure consists of a 78-bed ward, two-bed ICU, phlebotomy stations, pharmacy, bioanalytical labs with LCMS and HPLC machines.

The company boasts of a rich bank of healthy volunteers drawn from the local community in Faridabad and

Fortis Clinical Research Ltd (FCRL) is a leading full service Indian CRO operational since 2005, providing clinical research services to the pharmaceutical, biotechnol-ogy and device companies across the globe. It comprehensive drug-devel-opment services focused on expert quality and cost effec-tive solutions for end-to-end management of clinical tri-als. Its state-of-the-art facil-ity is spread over 19,000 sq. ft. and four floors of the Sun-flag Hospital and Research Center in Faridabad (near Delhi).

Delivering quality services

Delhi/NCR and is currently conduct-ing bioequivalence studies with ge-neric products in healthy volunteers and clinical studies (phase 1 to IV) in healthy volunteers and patients at investigator sites as its main service offering. It has also conducted num-ber of BE studies in young, healthy female volunteers, post-menopausal female volunteers.

According to Mr Anil Pan-war, CEO, FCRL there are many areas where it is ahead of its competi-tors. Our central labora-tory was Indias first to get ISO 15189:2007 NABL and CAP accreditation. We have experience of over 550 clinical trials for over

35 therapeutic segments. We have a 24-hour dedicated sample archiving facility, dedicated clinical research service department and real time web-based online reporting systems. We extend the services to about eight million patients annually. The FCRL team excels in end-to-end manage-ment across all the clinical and phar-macovigilance studies, concluded Panwar. BS

With huge infrastructural built up and manpower, Fortis Clinical Research has maintained its consistent performance over the period of time, gaining some firm ground for overall growth

CoMpanYFortis Clinical research limited

BuSineSSClinical research/drug development services


FCRL has 90 full time professionals with expertise in medicine, pharmacology, pharmacy,

pharmaceutics, bioanalytics, nutrition and statistics. Fortis has conducted more than 280 BA/BE studies since

its inception in 2005 till date.

Chief Executive Officer: Anil Panwar

biotech companies

TOP 20


400 employees. In the recent years, the company has invested to devel-op a state-of-the-art R&D facility in Bangalore, which is not only involved with fulfilling the requirements of local customers but also in the ap-

plication development for the needs of global entities. It entered into an exploratory agreement with Sea6 Energy, a young start-up involved in using novel methodologies for the conversion of seaweed into biofuels. Novozymes will be involved in iden-tifying the kind of enzymes that are required for the conversion of avail-able sugars in the biomass in the sea

Considered to be the largest sup-plier of industrial enzymes to industries across the spectrum in In-dia, Novozymes holds the dominant share of the enzyme market. The company provides enzyme solutions for the detergent, food, feed, textile, leather, oils and fats, beverage alcohol, and biofuel in-dustries. Novozymes India has recorded es-timated revenues of Rs 343 crore in FY 202-13, registering over 15 per-cent growth.

Novozymes has a sig-nificant business in India with over

Novozymes thrives on novelty

water, while Sea6 is developing the technology of cultivating the seaweed at offshore locations. The research alliance will use enzymes to convert seaweed-based carbohydrates to sug-ar, which can then be fermented to produce ethanol for fuel, fine chemi-cals, proteins for food, and fertilizers for plants.

The collaboration with Praj Industries, which started a few years ago for development of second generation bio-fuels, is also steadily moving ahead. The pi-lot production plant for the same is currently under evaluation. The team is now exploring the use of local biomass

such as corn cobs and bagasse for the production of biofuels. Addition-ally, Novozymes also launched Cellic CTec3 in India. It is an enzyme for better conversion of biomass to etha-nol. Novozymes is looking to main-tain its growth in the next couple of years and increase awareness for en-vironmentally friendly solutions in industrial processes. BS

The company believes in constant innovation to leverage technology platform and growing its portfolio of sustainable solutions to various businesses

CoMpanYNovozymes South Asia

BuSineSSIndustrial enzymes


Novozymes entered into an agreement with the Holck-Larsen Foundation to work with Danish universities to set up a scientist exchange program, the first of its kind between India and Denmark. The new

exchange program is funded to the tune of DKK 2 million a year by both the partners. The program will run from 2013 to 2019.

Regional President: G S Krishnan

biotech companies

TOP 20


R&D projects in collabora-tion with the Texas Uni-versity for the cotton crop. They are currently evaluating different lines

for their efficacy. Through this study, certain genes from

Ankurs proprietary germplasm have been identified that offer drought tolerance. The next step would be to identify markers that are responsible for these traits.

Dr Ashwin Kashekar, general man-ager, R&D, Ankur Seeds spoke about

other PPPs that Ankur has been a part of in recent times. We are cur-rently in a public private partnership with ICGEB, for researching virus re-sistance in tomato. This project was partly funded by DBT and Ankur. A few years back, we had also signed an MoU with GKVK (Gandhi Krishi Vig-yan Kendra), Bangalore, for screen-ing germplasm and identifying lines

Riding high on its Bt cotton suc-cess, Ankur Seeds has recorded revenues of `341 crore for this year, while keeping a strong pipeline of re-search projects in store. Two new hy-brid varieties of cotton were also in-troduced on a large scale during the year; Ankur 3034 BGII and Ankur 216 BGII. Hybrids were launched across the cotton growing zones of India, that were suitable for both irrigat-ed and rain-fed conditions, in-cluding intra and inter specific Ankur-bred hybrids.

Ankur has initiated both transgenic and classical breeding

Public private partnerships pave the way

that exhibit traits of water efficiency and drought tolerance. Additionally, we have also done some contract re-search work with Cornell University centering on genotyping and marker associated research.

A great example of technology trans-fer through a public private part-nership (PPP) has been with Rajen-dra Agricultural University, Bihar. Researchers at the university had done early research and developed a more efficient crop variety. After the technology transfer from the public

university, Ankur is all set to produce and market the same variety under a royalty shar-ing agreement.

The focus for Ankur Seeds has been on field work through demonstrating use of biotech material and helping famers understand good manage-

ment practices like drip irrigation to get higher yields. Activities like Farmers field days, that had been conducted on large scale also helped in the business growth. Ankur Seeds now has multicrop R&D proposals on board seeking government approvals for Biosafety Research Level (BRL) trials, which it hopes to get started in the next year. BS

The year saw Ankur Seeds enter into a number of collaborations ether through MoUs or public private partnerships.

CoMpanYAnkur Seeds

BuSineSSSeed dealers and distributors


Ankur conducts research through breeding programs on 16 different

crops. It claims to be the only company in the world to have developed a cytoplasmic male

sterility system that can be used in hybrid seed production.

Managing Director: MG Shembekar

biotech companies

TOP 20TOP 20


The company is planning invest-ments to the tune of `800 crore over the course of the next five years. While staying true to the philosophy with which it was set up, the bulk of IILs revenues are through domestic

sales to governments and through the private market. However, its bio-science exports have increased from 6.95 percent to almost 14 percent.

This year, Raksha Ovac became the largest selling veterinary brand in In-dia with sales exceeding `125 crore. Raksha Ovac is a vaccine for Foot and Mouth disease that was launched more than three decades ago has

From a single vaccine producing government aided unit, Indian Immunologicals (IIL) has evolved over the years to gain formidable share in human vaccines and gar-ner a leadership position in ani-mal vaccines. During FY 2012-13, it grew at 27 per-cent to achieve revenues of `325.65 crore. It also crossed the `400 crore fig-ure for its total turnover. Mr Anandkumar, deputy managing director, attrib-uted this performance to an overall growth in both animal and human vaccine products.

Socially conscious

been a major contributor to pre-venting loss of cattle. While IIL has produced more than a billion doses of FMD vaccine since inception, the FMD vaccine plant in Hyderabad today has a capacity to manufacture 240 million doses annually.

IIL also has plans to set up another facility exclusively for producing the FMD vaccine at Puducherry. The proposed new facility will be the larg-est one in the world for FMD vaccines with a capacity to produce 500 mil-lion doses of the vaccine. IIL is one

of the few companies which has exported the vaccine to other countries in a super-concentrate form.

In terms of human vac-cines, IIL has also devel-oped a pentavalent vaccine that is currently awaiting approval for Phase II/III trials. Vaccines for ne-glected diseases like chi-

kungunya and Japanese Encephalitis are also currently under research. When it comes to their oral HPV vac-cine, IIL has completed its toxicology studies and is seeking approval for further studies.

Other vaccines like DPT, TT and vero cell Rabies vaccine that are produced at IIL are directly supplied to the In-dian government. BS

Indian Immunologicals Raksha Ovac became the largest selling veterinary brand in India with sales exceeding `125 crore.

CoMpanYIndian Immunologicals

BuSineSSmanufacturing of animal and human vaccines


IIL also markets the worlds first combination viral and bacterial vaccine

for bovines in the Raksha Triovac vaccine covering FMD, Haemarroghic septicaemia (HS) and Black Quarter (BQ) vaccine. It has set itself apart in the field of animal health by being the only one to produce vaccines for

companion animals like canines.

Managing Director: K V Balasubramaniam

biotech companies

TOP 20


of success in the first year of launch. The other important vac-cines which continue to receive increasing

support from the physi-cian community were Cer-

varix and Rotarix.

Another important development in 2013 has been the joint venture be-tween GSK and Biological E. This

is a 50:50 joint venture (JV) for the early stage research and develop-ment of a six-in-one combination pediatric vaccine to help protect children in India and other develop-ing countries from polio and other infectious diseases. If approved, the vaccine, which would combine GSKs injectable polio vaccine (IPV) and Biological Es pentavalent vaccine for diphtheria, tetanus, whooping cough (whole cell pertussis), hepa-

In 2012-13, GSK is estimated to have recorded `312 crore in reve-nues from its vaccines business. Ear-lier, the company had limited pres-ence in many important therapeutic areas such as life saving can-cer drugs, cardiology and preventive vaccines. How-ever over the past few years GSK took a number of stra-tegic steps such as increasing the field force to correct this.

Synflorix, a 10-valent pneu-mococcal vaccine, was intro-duced recently and achieved a landmark distinction of being the first brand in the Indian pharmaceu-tical industry to achieve a high level

Distinction in pneumococcal vaccines

titis B, and Haemophilus influenza type b, and hence could be the first of its kind. The vaccine would enable fewer injections for children thereby improving compliance in immuniza-tion schedules. Also, the fully liquid formulation of the vaccine would be ready to use with no additional ingre-dients or materials required, freeing up space at local storage facilities.

The JV will bear the development costs for the candidate vac-cine, which is expected to en-ter phase 1 development in the next two years. A small initial cash investment will be made by both companies to cover start-up costs for the JV and subsequent development costs will be split equally.

Supply chain management of vaccine has also shown improvement over the last year, at GSK. An overall positive trend in supply performance especially in vaccines helped in sup-porting the larger business perfor-mance as well. GSK has adopted a flexible pricing policy in order to expand access to its products, both vaccines and medicines, based on a countrys ability to pay. This has resulted in significant reduction in prices. BS

The vaccine arm of GlaxoSmithKline registered a good growth while consolidating its position as one of the market leaders in pediatric vaccines. GSKs overall range of vaccines are said to have grown faster than the overall vaccines market.

CoMpanYGlaxoSmithKline

BuSineSSSales of vaccines


According to an IMS Health report, GSK holds a leadership position

with a market share of 24.9 percent. During the year GSK was

also awarded the Frost and Sullivan Paediatricians Award for Vaccines

company of the year.

Managing Director: Dr Hasit Joshipuria

biotech companies

TOP 20


encephalitis, pandemic influenza, chikungunya, and staphylococcus aureus.

The company has developed a three-dimensional business model with emphasis on biogenerics, con-tract manufacturing and research,

and novel products. This strategy has given Bharat Biotech the abil-ity to earn revenues in the short and medium term while focusing on novel patent protected products for the long term. The company claims to have the largest manufacturing capacity for making hepatitis-B (10 crore doses), typhoid vaccine (five

During the FY 2012-13, the Bharat Biotech registered an annual turnover of `299.83 crore as against `277.7 crore recorded in FY 2011-12. Though the company has displayed marginal growth during this fiscal year, it is banking upon new oppor-tunities. It has invested a significant amount of money on conduct-ing clinical trials of seven of its products. These products in-clude therapeutics and vaccines that are at an advanced stage of development. It has product development projects in vary-ing stages for the vaccines and therapeutics, such as malaria, rotavirus, typhoid, Japanese

Betting on Rotoavac

crore doses) and rabies (80 lakh doses).

Rotavac, the first oral rotavirus vac-cine developed by Bharat Biotech has successfully completed the phase III clinical trials, being one of the first and largest phase III clinical trial in Indian history encompassing 10,000 infants. The company has invested `231.7 crore ($50 million) in the clin-ical trials, with funding assistance from Gates Foundation.and the De-partment of Biotechnology, Govern-

ment of India. With the trials data reporting 60 percent ef-ficacy and no significant side effects, the Bharat Biotech is set to approach the DCGI in July, 2013 for approval to produce the vaccine.

Rotavac represents the successful research and de-

velopment of a novel vaccine from the developing world with global standards, said Dr Krishna M Ella, chairman and managing director, Bharat Biotech. It is a testament of our strong vision and commitment to develop affordable health care solu-tions for infectious diseases. BS

Armed with a robust product pipeline, Bharat Biotech has further strengthened its position as the producer of quality indigenous vaccines. With new launches in coming years, it is set to tap new opportunities

CoMpanYBharat Biotech

BuSineSSvaccines and Therepeutics


Bharat Biotech increased its focus on new novel vaccine development program for infectious diseases.

It also focuses on exports market through renewed marketing team

in emerging market.

Chairman and Managing Director: Dr Krishna M Ella

biotech companies

TOP 20


Tulip hopes to grow at rate that is on par with market trends, at

an average of 12 percent. It would also focus on introducing new

and innovative products that can influence trends in diagnostic testing.

it has been processed and loaded on a specially designed chip. The results are then displayed in less than 30 minutes, thus making it very effective for quick diagnosis.

Currently the instrument can analyze samples for seven diseases. These include malaria, tuberculosis, den-gue, malaria, swine flu, chikungunya, HPV and salmonella. Mr Tripathi, director, Tulip Group, says that with the India launch they hope to gauge market reception and then announce it in other countries in a years time.

In addition to manufacturing in vi-

Last year saw Tulip soft launch a unique product in the market that it hopes will be a game-changer in the diagnostics field. RT PCR or Tru-elab Real Time PCR is a product that is borne of MolBioDiagnos-tics, a joint venture between Bigtec and Tulip that was initiated in late 2011. Essen-tially working on the prin-ciples of PCR for diagnosis, it is an easy to use point of care device that consists of a handy instrument that ana-lyzes a patient sample after

biotech companies

tro diagnostic reagents and kits, Tu-lip also produces biochemistry kits, high technology disinfectants, de-hydrated culture media, bases, and other products such as supplements, stains, laboratory reagents, antibiotic sensitivity discs, plant tissue culture media and chemicals. It also does the marketing of immunoassay reagents, semi automated and automated ana-lyzers for the IVD Industry.

Tulip currently has eight manufac-turing sites in Goa and two others in North India. The recent expansion of a plant in Uttarakhand, which is spe-cifically for in vitro diagnostics, has

been a major endeavor for Tulip during the year. Ad-ditionally, the company will also be making substan-tial facility additions in the times to come, depending on the demand.

A number of other products in the diagnostics range

were launched last year, which in-clude rapid diagnostic tests for blood grouping and drugs of abuse. Ad-ditionally enzymatic tests for bio-chemistry, new dehydrated culture media, plant tissue culture were also introduced into the market. Almost 40 percent of Tulips revenues come from exports. Currently it exports the entire range of products to over 70 countries across the world. BS

One of the leaders in the diagnostics industry, the Tulip group grew at almost 16 percent, higher than the industry average.

Director: Deepak Tripathi

Product launches galore

CoMpanYTulip Group

BuSineSSmanufacturing in vitro diagnostics, reagents and rapid diagnostic tests


TOP 20


over the last few years.

Haffkine Biopharmaceuticals has a long history of indigenously manu-facturing biological products. It was established in 1975 as a Government of Maharashtra undertaking to pro-duce life saving vaccines, antisera and pharmaceuticals. Since then,

the company has come a long way and also set up a GMP facility that is prequalified by World Health Orga-nization for supply to United Nations Childrens Fund (UNICEF). It was one of the first public sector vaccine-manufacturing units to get a WHO accreditation for a trivalent OPV al-most seven years ago.

Haffkine Biopharma has three fa-

The production of OPV doses is under full swing at Haffkine, where 390-400 million doses were manufactured and supplied to vari-ous agencies last year. Haffkine has had a major role in supplying oral polio vaccine for the last 38 years. While vaccines fetched the bulk of the revenues, other biological ther-apeutics also contributed to the total bioscience revenues of `253.41 crore. A senior of-ficial commented that their ability to meet the demand of supplying OPV doses promptly has been the com-panys strong suit and helped it be on an upward curve of growth

Polio vaccine makes the difference

cilities in Maharashtra for differ-ent products. The expansion and modernization of these sites is an ongoing process, quipped a com-pany official. Located n the heart of the city, amidst various cen-tral and state research institutes and hospitals, the Mumbai facility manufactures the oral polio vaccine as well as the DPT vaccine. Cur-rently the production facilities for the DPT vaccine are undergoing a modernization exercise. Another

facility at Jalgaon produces beta lactam products and oral rehydration salts. Haff-kine remains one of the few companies that produces life saving products such as anti-sera and antivenoms. These are manufactured in Pimpri

where about 400 equines are also maintained to produce various an-tisera. Haffkine is also the only manufacturer of scorpion venom antiserum in the country.

Over the last year, the company also boosted its exports to other ASEAN, African and Latin American coun-tries. BS

A major contributor to the Pulse Polio Immunization Program, Haffkine bagged a number of contracts from the Indian government as well as UN agencies that provided a 62 percent spurt in its revenues during FY 2012-13.

CoMpanYHaffkine Biopharmaceuticals

BuSineSSvaccines, antisera, pharmaceuticals


With the increasing traction in place for eradicating polio, Haffkine hopes to continue producing OPV doses to meet the demand, in the

years to come as well.

biotech companies

Managing Director: Sambhaji Zende

TOP 20


biotech companies

Dr Bharat Char, lead, biotechnology, Ma-hyco is very hopeful of the pipeline of trans-

genic crops that are cur-rently being researched at

Mahyco. He says, Mahyco has a her-bicide tolerant cotton variety in the late stages of development. Roundup Ready Flex is currently in the final stage of regulatory approval and will be launched in the next 1-2 years.

We added a single gene to BGII that makes it resistant to herbicide, and hence farmers can easily protect the crops weeds. It will also help them maintain their fields more easily and result in less loss of nutrients and tillage.

Scientists are also working on devel-oping drought and salinity tolerant varieties by using both traditional breeding techniques and biotech ap-

Troubles erupted last July when the Maharashtra government passed an order to ban the sale of Mahycos Bt cotton seeds in the state. The ban came close on the heels of reports about the artificial shortage of Bt cotton seeds being created, allegedly by the company, in the market leading to seeds being sold in the black market at more than twice the government stipulated rates. This has affected Mahycos revenues with a loss of almost of 21 percent as compared to the previous year.

Controversies hit market share

proaches. Additionally they are in early stages of producing virus and fungi resistant crops such as cotton, chilly and okra. Simultaneously, work is in progress for developing varieties that will increase fertilizer efficiency thus reducing the amounts required by the farmer and subsequently the costs associated with it.

Mahyco, through public private ini-tiatives in India, Philippines and Ban-

gladesh had developed a Bt brinjal variety. Currently, in India, a moratorium has been placed on this crop since three years, thus put-ting the future of this crop in jeopardy. However field trials for the same have been done in Bangladesh and the data is being eval-uated separately. In the Philippines too, biosafety

reviews for Bt brinjal are currently underway. If those prove successful, the crop will be introduced in those countries in the next few years.

With growing acceptance of BGII, Mahyco has started phasing out BGI seeds. In the future, Dr Char opines more research on how to increase pro-ductivity by adopting the right agro-nomic practices that can allow mecha-nized harvesting will be key. BS

Last year, Mahyco saw a drop in its revenues. This was on account of ban on sale of its Bt cotton seeds in Maharashtra. Having sold 26.5 lakh Bt cotton packets, Mahyco recorded revenues of `264 crore.

CoMpanYmahyco

BuSineSSProduction of seeds for Gm crops, field crops, vegetables and transgenic


Mahyco employs over 275 scientists in its plant breeding and biotech

programs. A large facility in Dawalwadi, near Aurangabad, develops not only

improved seeds but also other products that are associated with Bt technology such as diagnostic kits for detecting

the Bt gene.

MD: Raju Barwale

TOP 20


Currently Advanced Enzymes ex-ports to more than 45 countries. The company has had a 29 percent CAGR growth from FY 2008 to FY 2012 with a growth in PAT of 61 percent CAGR during the same period. Recently private equity firm Kotak had also in-

vested in the company. Currently Ad-vanced Enzymes manufactures more than 50 different enzymes for differ-ent industries such as pharmaceuti-cals, food, paper, leather and more. Of the different types of enzymes, the demand for food and feed enzymes showed maximum growth in the last financial year.

One of the important milestones

While most companies, life sci-ences space continue to stick to private source of funding for their operations, Advanced Enzymes will soon enter the relatively small league of Indian biotech companies that are listed on the stock exchange. Mr C L Rathi, managing direc-tor, has said, We will be going in for an IPO within this financial year. We have already filed the necessary documents with SEBI to be listed on the National Stock Exchange (NSE) as well as the Bombay Stock Exchange (BSE).

Will go public

achieved last year was the comple-tion of its fully automatic manufac-turing facility with a 240m3 capacity in Indore. Mr Rathi proudly says that this was done entirely using internal resources and proprietary knowl-edge. Though, this led to a few de-lays, it proved to be a great learning experience for the management.

An emphasis has been laid on pro-viding eco friendly solutions for the detergent, paper, food, fruit process-ing and biofuel industries. Moving

ahead, Mr Rathi said that they would focus on fermen-tation enzymes. He added, While we see good growth in enzymes space for the food and feed industry, we also plan to enter the deter-gent enzyme space in a big way soon.

Following its keen strategy to expand overseas, Advanced En-zymes have enhanced its product reg-istrations abroad and also acquired a US-based retail marketing enzyme company last year. The acquisition will aid its expansion plans in the West. Moving ahead, it will target large companies in Europe and oth-er countries that import enzymes in bulk quantities, and those that prefer eco friendly enzymes. BS

For FY 2012-13, Advanced Enzymes has declared revenues of Rs 229.36 crore, with exports constituting more than 62 percent of its total sales.

CoMpanYAdvanced enzymes

BuSineSSenzymes for Human Health Care and Nutrition, Animal Nutrition, Food Processing and Non-Food Processing


Advanced Enzymes has over 330 employees of which 35 are involved in R&D activities. In addition to the

manufacturing facility in Indore, Advanced Enzymes has two facilities

in Thane focusing on R&D and had plans for further expansion in the

near future as well.

Managing Director: C L Rathi

biotech companies

TOP 20


biotech companies

In a bid to expand its op-erations, Rasi acquired

the Bayer Crop Sci-ences hybrid corn business recently. About the move, Mr

Ramasami says, We took this step to increase

our market share in the hybrid corn market. This step will hopefully al-low Rasi to double its share in the hy-brid corn seed market. Rasi will now be able to add five to six hybrid vari-eties to its existing portfolio besides allowing Rasi to access Bayer Crop sciences corn germplasm. Officials have stated that this would help them strengthen their own germplasm

bank and further develop hybrids. It will also give access to expertise and breeding stations in Bangalore, Hy-derabad and in North India.

Rasi Seeds has set a target to increase the corn seed production volumes to around 10,000-12,000 tonnes in the next few years while exploring differ-

One of the earliest adopters of Bt cotton technology in India, Rasi had become an early entrant into the market. However a number of issues such as increased competition and environmental factors resulted in a downward trend in the growth curve. Last year, Rasi released two new cot-ton hybrids which have been well re-ceived this Kharif season by farmers across the country. Rasi cur-rently has over 20 Bt products under BGI and BGII for differ-ent zones of the country. Rasis Bt cotton revenue during FY 2012-13 was `292 crore. The company expects this year to be a better one and is estimat-ed to reach `575 crore through Bt cotton sales.

Dip in Bt cotton revenues

ent markets in South-East Asia. Cur-rently both Rasi and Bayer had vol-umes of around 3000 tonnes of corn seed a year.

Rasi Seeds has a number of existing collaborations with both national and international institutes to devel-op high yielding hybrid varieties such as Tamil Nadu Agricultural Univer-sity, Madurai kamaraj University, In-dian Agricultural Research Institute and University of Ottawa, Canada, and International Rice Research In-stitute, Phillipines. Some of these are under DBT schemes in a public pri-vate partnership mode.

Another partnership Rasi Seeds entered into was with Evogene, an Israel based firm to introduce its hybrid rice varieties. Under the agree-ment, Rasi will get an exclu-sive license to introduce Evo-gens drought tolerant and yield enhancing gene traits into its own varieties of hy-brid rice. Evogen had iden-

tified a total of 24 genes, that have been validated in model plants and that possess both drought resistant and yield enhancing traits.

Besides this Rasi also has a fledgling business of distributing vegetable seeds under HyVeg brand. BS

With area under Bt cotton reaching maximum capacity and an erratic monsoon in some parts of India, Rasi Seeds recorded a sizable dip in its FY 2013 bioscience revenues.

CoMpanYrasi Seeds

BuSineSSField crops, Bt cotton, hybrid vegetable seeds


Rasi Seeds has been the first to engineer Genetic variability to suite various agro climatic

zones with wider adoptability by producing hybrids of various staple lengths, high strength and a biotic

stress tolerance in cotton.

Chairman and Managing Director: M Ramasami

TOP 20


rank >> 21Sanofi india (Formerly aventis pharma)Business: Insulin and insulin delivery devices

Revenue: `213.00 croreMd: shailesh ayyangar

lantus, sanofis leading brand of long-acting insulin grew by 25 percent in value terms and commands a market share of 11.9percent and continues to be the 2nd leading brand in insulins in terms of value. sanofi launched an indigenously manufactured reusable insulin pen, allstar in 2012, and priced it significantly lesser than its competitors.

rank >> 22 Krishidhan Seeds Business: plant breeding, seed production, processing and packing of high quality seeds revenue: rs 199.81 crore

Managing director: sushil Karwa

Krishidhan sold 19.37 lakh plus packets of bt cotton seeds during Kharif 2012 season. It entered into a public prvate partnership under which farmers were supplied with mahacot and mahacot-2 cotton seeds at affordable rates.Currently the bt cotton acerage under Kspl seeds is 13.75 lakh acres with a reach of around 6.65 lakh farmers in India.

rank >> 23 panacea Biotec

Revenue: `190.00 crore*Business: r&d, manufacturing and marketing of pharmaceuticals, biopharmaceuticals and vaccines

Joint managing director: dr rajesh Jain

the panacea biotec has been reeling under pressure to reclaim its growth path that has hit a roadblock. once among top three companies in India, it had slided down in its biotech revenue collections clearly as an outcome of delisting of pentavalent vaccines from the whos list of prequalified vaccines. It is now aggressively ramping up its production capacity, as well as introducing new business lines.

rank >> 24 concord Biotech Business: production of biopharmaceuticals through fermentation

Revenue: `174.50 croreMd and ceo: sudhir vaid

Concord biotech recorded a growth of 20 percent in their revenues. It also launched new products including one in oncology, two each in antifungal and immunosuppressant segments as well as three antibiotics. this year, Concord also offered contract research and contract manufacturing services to biopharmaceutical companies for developing molecules through fermentation and semi-synthesis.

rank >> 25 Bharat immunologicals & Biologicals corporation Business: vaccines and diagnostic kits

Revenue: `172.78 croreManaging director: dr sreeshan raghavan

bIbCol works as a central public sector unit, under the department of biotechnology. It manufactures and produces a range of pharmaceuticals products such as oral polio vaccines, zinc tablet and diarrhea management kits. with the revamping of manufacturing setup and catching up on production, the company has been able to do a remarkable turnaround. there has been growth of more than 200 percent for the company.

rank >> 26 ecron acunova Business: Contract research services

Revenue: `153 crorechairman & Managing director: d a prasanna

ecron acunova has a direct presence to 28 countries across asia, europe and americas. It is built a competency in contrast agent studies and stem cells. It also successfully performed a first-in-man study in singapore for an Indian nCe. last year it stepped up its service to generic industry.

rank >> 27 anthem Biosciences Business: pharmaceuticals, biotechnology, agro, specialty Chemicals, veterinary

Revenue: `140.00 croreceo: mr. ajay bharadwaj

a discovery research alliance partner that provides services in various areas, anthem grew by 40 percent in the Fy 12-13. this year it completed a large scale facility expansion for manufacturing. additionally, new labs for discovery biology including in vitro, in vivo and pharmacology labs were inaugurated. also fermentation facilities were installed.

rank >> 28 company:dr Reddys laboratories

Business: biosimilar production and marketing

Revenue: `110 crorechairman: g v prasad

dr reddys currently has four biosimilars in the market and eleven in various stages of development and commercialization. there is a fully integrated biosimilar development team that includes r&d, clinical operations, medical affairs and global pharmacovigilance. also, drl has built a who certified cgmp manufacturing facility, which includes e.coli and mammalian cell culture facilities.

rank >> 29 Span diagnostics Business: In vitro diagnostics and medical devices

Revenue: `99.47 croreMd: veeral desai

span diagnostics, a leading in vitro diagnostics products manufacturers products are marketed across India and exported to more than 90 countries. during the last year, span executed a large government order to supply hIv screening test to naCo under national aIds Control program and launched an indigenously developed analyzer.

biotech companies

TOP 20+


rank >> 30 advinus therapeutics Business: drug discovery and contract research services

Revenue: `97 crore*ceo: dr rashmi barbhaiya

advinus therapeutics consists of two business units, one for drug discovery and the other for providing contract research services. recently takeda pharmaceutical entered into a research collaboration with advinus therapeutics ltd. to initiate a three-year discovery collaboration focused on novel targets for major therapeutic areas, including Inflammation, Cns, and metabolic diseases.

rank >> 31 RFcl (diagnova) Business: diagnostics

Revenue: `73.20 croreexecutive vice president, diagnostics: veena Kohli

diagnova is a strategic business unit of avantor performance materials having two sub-divisions In vitro diagnostics and life sciences group. It offers quality products and services under immunochemistry, clinical chemistry, hematology, microbiology, rapid cards, flow cytometry, point-of-care-testing instruments and tools for life sciences research. In march 2013, there was a launch of fully automated Chemi luminescent Immuno assay (ClIa) instruments and reagents from snibe.

rank >> 32 Max neeman international Business: Clinical research services

Revenue: `70.00 croreceo: dr ajoy Kumar

max neeman International was started in 2001 and over the years, it has grown into a full service Clinical research organization (Cro), providing services for the successful conduct of phase II-Iv clinical and device trials for small and mid-sized international pharmaceutical, biotechnology, medical device and nutraceutical companies.

rank >> 33 hester Biosciences Business: animal health products and vaccines

Revenue: `61.90 croreceo and Md: mr.rajiv gandhi

hester biosciences is an veterinary vaccine and health products company that produces 11 types of live and 28 types of inactivated poultry vaccines along with large animal vaccines. the state of the art manufacturing facility has a capacity of 4.8 million doses.this year a bivalent mareks disease live vaccine for the poultry was developed.

rank >> 34 ocimum Biosolutions Business: bioinformatics tools and services

Revenue: `60.00 crore*ceo: anu acharya

ocimum biosolutions started as a pure play bioinformatics company and slowly expanded its scope to adding wet lab capabilities and strengthened it through its multiple acquisitions. today it is a leading integrated genomics company providing comprehensive genomic reference databases, life science lab information management solutions, glp-compliant microarray services and essential research consumables. It has created worlds largest commercial gene expression databases bioexpress and toxexpress

rank >> 35 company: cadila healthcare Business: developing and marketing biopharmaceuticals, biosimilars

Revenue: `57.34 crore*cMd: pankaj patel

the biotech division at Cadila healthcare currently has four biosimilars registered in the market, namely peg gCsF, epo, pth for the treatment of osteoporosis and peg IFn for hepatitis C treatment. It plans to launch 12 biosimilars by 2015. Cadila has planned investments of rs.300 crore over the next few years for its biotech division.

rank >> 36 Strand life Sciences Business: bioinformatics tools and services

Revenue: `55.00 crore*

Founder & chairman: dr vijay Chandru

strand creates end-to-end solutions for clinical genomics, pharmaceutical r&d, and basic genomics research by integrating in vivo, in vitro and in silico biology. It empowers scientists and clinicians to transform raw data into actionable insights and deliver precision through genomics. It aims to transform life sciences research with application of advanced computational technologies.the company received dbt & bIraC Innovator award 2012 under the category of best innovation in healthcare for its hepatotoxocity prediction platform (heptox).

rank >> 37 company: Maps enzymes Business: production and marketing of enzymes

Revenue: `54.28 crorecMd: piyush palkhiwala

maps produces enzymes used in the textile, detergent, alcohol, animal feed, pulp and paper, and baking industries. Currently maps markets more than 130 enzymes. started in 1975, it exports its products to a number of countries including Iran, Italy. the range of enzymes includes amylases, proteases, cellulases, xylanase, glucoamylase and more.

rank >> 38 oncquest laboratories

Revenue: `48.00 croreBusiness: diagnostics

Vice president, operations : dr ravi gaur

with a decade of experience under its belt, oncquest is known for its excellence in clinical diagnostics and its core competence in cancer diagnosis. From its first avatar as an r&d focused entity, oncquest has evolved into a reference laboratory in the field of oncology, and more recently into a multi-

biotech companies

TOP 20+


platform pathology services provider with a core focus in molecular pathology, and surgical pathology services.

rank >> 39 camson Biotechnologies business: agriculture biotechnology

Revenue: `24.45 croreceo: santosh nair

Founded in 1993, Camson combines traditional knowledge in agriculture with latest advances in safety and protection to market a wide range of products. these include hybrid seeds, bio-fertilizers and biocides that are non-poisonous, eco-friendly and residue-free. It used intragenics to develop high yielding, disease tolerant germplasms. It has also developed Champavati, the multi-colour flesh watermelon and bagvati, the yellow flesh watermelon.

rank >> 40 celestial Biolabs Business: biopharmaceuticals

Revenue: `21.60 croreManaging director: dr aditya narayan singh

Celestial biolabs ltd (Cbl) is an Iso 9001-2008 certified company with three decades of experience in drug discovery adopting Insilico process. Currently, Celestial biolabs is engaged in bio pharmaceuticals formulations, consisting, herbal, nutraceuticals, enzyme Formulations. peptide development through biological route is one of its priority area of interest.

rank >> 41 auriga Research

Revenue: `21.00 croreBusiness: Clinical research services

head, project planning and management: dr manoj Karwa

auriga research is a contract research organization involved in the development, marketing authorization and registration of quality pharmaceutical, herbal, cosmetics, biological, medical devices and biotechnology products in India and rest of the world. the company supports numerous clients for registration of new

drugs covering regulatory consulting, bioequivalence studies and clinical trials.

rank >> 42 Bhat Biotech*

Revenue: `15.00 croreFounder, cMd: shama bhat

this diagnostic company is based in bangalore and provides tests for hepatitis, malaria, dengue, Chikungunya, swine Flu (h1n1), syphilis, tb, etc. It recently launched bhat gluco-scan glucometer and indigenously develo

Date post:	16-Oct-2015
Category:	Documents
Upload:	manasi-kadam
View:	76 times
Download:	0 times

ABLE 2013 Survey

Documents